Risk-adjusted therapy for newly diagnosed multiple myeloma with +1q
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a treatment plan that is adjusted based on the risk level of your multiple myeloma, especially if you have a specific genetic change called +1q. It aims to find the best therapy for you while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older (or 65+ and generally healthy enough for treatment).
- You must have been newly diagnosed with multiple myeloma (a type of blood cancer).
- Your major organs (like kidneys and liver) must work well enough for cancer therapy.
- You cannot have a serious active infection that needs treatment.
- You cannot have unstable heart problems like severe chest pain or uncontrolled rhythm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with newly diagnosed multiple myeloma whose cancer responded to initial treatment but still has tiny traces (minimal residual disease, or MRD). The trial will test if adjusting the next phase of therapy based on MRD levels can improve long-term outcomes.
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
This trial tests a combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people with newly diagnosed high-risk multiple myeloma who cannot or choose not to have a stem cell transplant. It aims to see if this treatment helps control the disease better.
This trial tests a new drug, BMS-986453, for people newly diagnosed with multiple myeloma. It aims to see if the drug is safe and works well for those who cannot or choose not to have a stem cell transplant.
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.